Enhancing the effect of car-engineered T cells by means of nucleic acid vaccination

US10799534B2 · kind B2 · utility

Assignees

• BioNTech Cell & Gene Therapies GmbH · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Katharina REINHARD · Mainz, DE
• Petra Simon · Mainz, DE
• Karolina Anna Mroz · Wiesbaden, DE
• Kathleen HOBOHM · Kelkheim, DE

Key dates

• Filing date: May 9, 2016
• Grant date: Oct 13, 2020
• Expiry date: Oct 9, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.